Purinergic (P2Y) Receptors

Clopidogrel thiolactone is a P2Y12 receptor inhibitor, is a potent antiplatelet agent.

N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM).

Clopidogrel is a well-known and orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It is orally and intravenously available and has potent antiplatelet effects.

TAK-024 is a platelet inhibitor with IC50s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively.

Vicagrel, an acetate derivative of Clopidogrel, is a P2Y12 platelet inhibitor potentially for the treatment of thrombosis.

AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.

Uridine-5'-diphosphate disodium salt functions as an agonist for the P2Y6 receptor, exhibiting high specificity with an EC50 of 300 nM (pEC50=6.52 for the human P2Y6 receptor). This endogenous metabolite plays a crucial role in catalyzing the glucuronidation of various substrates and is also instrumental in RNA biosynthesis. Its modulation of P2Y receptors has significant implications for research in cellular signaling and metabolic processes.

Uridine 5'-diphosphate sodium salt is a specific modulator of P2Y receptors, acting as a potent native agonist for the P2Y6 receptor with an EC50 of 300 nM and a pEC50 of 6.52, while also serving as a powerful antagonist at the P2Y14 receptor (pEC50 of 7.28). This endogenous metabolite plays a crucial role in the glucuronidation process of diverse substrates and is integral to nucleic acid biosynthesis, making it a valuable reagent in biochemical and pharmacological research focused on nucleotide signaling pathways and metabolic processes.

HDB-1 is a selective inhibitor of the P2Y14 receptor (P2Y14R) with an IC50 of 26 pM. This compound effectively blocks the activation of hepatic stellate cells by inhibiting the PKA/Raf1/MEK/ERK signaling pathway associated with P2Y14R, thereby mitigating the progression of liver fibrosis. HDB-1 is valuable for research into the mechanisms underlying liver fibrosis and the development of potential therapeutic strategies.

MRS2693 trisodium is a selective agonist of the P2Y6 receptor, exhibiting an EC50 value of 0.015 μM. It significantly reduces NF-kappaB activation while activating the ERK1/2 signaling pathway. MRS2693 trisodium demonstrates cytoprotective effects in models of ischemia-reperfusion injury in mouse hindlimb skeletal muscle, making it a valuable tool for research in cellular signaling and tissue injury responses.

P2Y14R Antagonist 4 is a potent oral antagonist of the P2Y14 receptor, exhibiting an IC50 value of 5.6 nM, indicating high binding affinity. This compound demonstrates anti-inflammatory activity by effectively reducing the release of proinflammatory cytokines, such as IL-1β, IL-6, and TNF-α, in response to LPS stimulation. P2Y14R Antagonist 4 is valuable for research applications in inflammation and immune response modulation.

PSB 0474 (3-phenacyl-UDP) is a selective and potent agonist of the P2Y6 receptor, exhibiting an EC50 of 70 nM. This compound modulates key biological activities, including the inhibition of cell proliferation and the enhancement of nitric oxide release in astrocytes and microglia. Additionally, PSB 0474 promotes apoptosis in astrocytes, making it a valuable tool for research in neurobiology and cell signaling pathways.

MRS2693 ammonium is a selective agonist targeting the P2Y6 receptor, exhibiting an EC50 of 0.015 μM. This compound demonstrates significant biological activity by protecting C2C12 skeletal muscle cells from TNFα-induced apoptosis and reducing NF-kB activation. Additionally, MRS2693 ammonium activates the ERK1/2 signaling pathway and has shown cytoprotective effects in a mouse model of ischemia-reperfusion injury, making it a valuable tool for research in cellular protection and signaling pathways.

Diquafosol is a potent P2Y2 receptor agonist that plays a significant role in modulating cellular responses associated with inflammation and apoptosis. It exhibits the ability to inhibit apoptotic pathways and reduce reactive oxygen species (ROS) generation, thereby promoting cell survival. Diquafosol is primarily used in research related to dry eye therapies, providing valuable insights into potential treatment strategies for this condition.

P2Y14R Antagonist 1 is a highly selective antagonist of the P2Y14 receptor, exhibiting an IC50 of 0.6 nM. It demonstrates significant antagonistic activity against P2Y14R, with both in vitro and in vivo efficacy, along with favorable pharmacokinetic properties. This compound effectively reduces the release of inflammatory mediators and mitigates cell pyroptosis through the NLRP3/Gasdermin D signaling pathway. P2Y14R Antagonist 1 is a valuable tool for research investigating acute gouty arthritis and related inflammatory conditions.

Diquafosol tetrasodium is a potent P2Y2 receptor agonist. It enhances fluid and mucin secretion on the ocular surface, making it an effective topical therapeutic option for the management of dry eye disease. This compound is valuable for research applications focused on ocular health and pharmacological interventions for dry eye conditions.